Publications by authors named "D Shoback"
Article Synopsis
- Conventional therapy for hypoparathyroidism helps with hypocalcemia symptoms but doesn't fix low parathyroid hormone (PTH) levels; TransCon PTH (palopegteriparatide) is being studied as a potential long-term treatment.
- A Phase 3 trial involved 82 adults across 21 sites in North America and Europe, with participants receiving TransCon PTH daily during a 156-week open-label period after an initial 26-week placebo-controlled phase.
- Results showed that by week 52, 81% of participants achieved normal serum calcium levels without needing conventional therapy, improved their quality of life, and experienced mostly mild to moderate side effects, indicating the treatment's sustained efficacy and safety.
Article Synopsis
- Individuals with chronic hypoparathyroidism on traditional therapy have a higher risk of kidney problems, and new treatments like palopegteriparatide could help improve kidney function while reducing reliance on conventional treatments.
- The PaTHway trial assessed the effects of palopegteriparatide on renal function over 52 weeks, showing promising results such as improved eGFR levels.
- After a year of treatment, many participants achieved normal calcium levels and stopped needing traditional therapies, with significant improvements in kidney function, especially in those with lower baseline eGFR.
Background: In the acute setting, PTH-independent hypercalcemia is typically treated with anti-resorptive agents such as zoledronic acid or denosumab. When these agents are no longer able to control hypercalcemia, several case reports have shown the utility of cinacalcet. However, it is not known if cinacalcet can be effective in patients naïve to anti-resorptive therapy or how cinacalcet ameliorates the hypercalcemia.
View Article and Find Full Text PDFContext: Chronic hypoparathyroidism is conventionally treated with oral calcium and active vitamin D to reach and maintain targeted serum calcium and phosphorus levels, but some patients remain inadequately controlled.
Objective: To assess long-term safety and efficacy of recombinant human parathyroid hormone (1-84) (rhPTH(1-84)) treatment.
Methods: This was an open-label extension study at 12 US centers.
Article Synopsis
- - Conventional therapy for hypoparathyroidism, which includes active vitamin D and calcium, doesn't address the underlying issue of parathyroid hormone (PTH) deficiency, making PTH replacement therapy an ideal treatment option.
- - The PaTHway trial tested the efficacy of the investigational drug TransCon PTH over 26 weeks, showing that 79% of participants on TransCon PTH reached normal serum calcium levels and could stop conventional therapy, compared to only 5% on placebo.
- - TransCon PTH significantly improved participants' quality of life and symptoms related to hypoparathyroidism, with a notable percentage achieving independence from traditional treatments and normal urinary calcium levels.